



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

**NOTICE OF ANNUAL GENERAL MEETING**

**NOTICE** is hereby given that the **07<sup>th</sup> (Seventh) Annual General Meeting ("AGM")** of the members of **ASSTON PHARMACEUTICALS LIMITED ("the Company")** will be held on Tuesday, 29<sup>th</sup> September, 2026, at 12:30 P.M. at the registered office of the Company situated at Office No. A-431, Balaji Bhavan, 4th Floor, Plot No 42A, Sector-11 CBD Belapur, Navi Mumbai, Maharashtra, 400614 (Deemed Venue) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the following business:

**ORDINARY BUSINESS:**

- 1. To receive, consider and adopt the audited financial statements, i.e., Balance Sheet, the Statement of Profit & Loss account and cash flow statement of the Company for the financial year ended 31st March, 2026 and the Reports of the Auditors and Board of Directors thereon**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

**"RESOLVED THAT** the Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2026 and the reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby considered and adopted."

- 2. To appoint Mr. Ashish Narayan Sakalkar, (DIN: 06601011) Managing Director of the Company, who retires by rotation as a director and in this regard,**

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

**"RESOLVED THAT** in accordance with the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, Mr. Ashish Narayan Sakalkar, (DIN: 06601011) Managing Director of the Company, who retires by rotation at this meeting, be and is hereby appointed as a Director of the Company."

- 3. To consider and approve the appointment of M/s Panchal S K & Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989w) as statutory auditors of the Company,**

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

**"RESOLVED THAT** pursuant to Section 139, 141, 142, 143 and other applicable provisions of the Companies Act, 2013 read along with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s), clarifications, exemptions or re-enactments thereof for the time being in force); and pursuant to the recommendation of the Audit Committee and the Board of Directors of the Company, approval of the Members of the Company, be and is hereby accorded for the re-appointment of **M/s Panchal S K & Associates, Chartered Accountants (Firm Registration No. 145989W; Peer Review Certificate No. 018089)**, as Statutory Auditors of the Company to hold office for the term of five consecutive years, commencing from the conclusion of 7<sup>th</sup> annual general meeting (to be held for the F.Y.2025-26) until the conclusion of the 12<sup>th</sup> AGM (to be held for the F.Y.2030-31)

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

at such remuneration plus applicable taxes and out of pocket expenses as discussed with the Auditors and duly approved by the Board of Directors of the Company, from time to time;

**RESOLVED FURTHER THAT** any Director and/or the Company Secretary be and is hereby authorized to file, sign and execute all forms and documents and to take all actions necessary to give effect to the proposed appointment;

**RESOLVED FURTHER THAT** Board of Directors (including any committee constituted thereof), be and are hereby authorized to do all such acts, deeds, matters and things as may be deemed proper, necessary, or expedient, including filing the requisite forms with the Ministry of Corporate Affairs or submission of documents with any other authority, for the purpose of giving effect to this Resolution and for matters connected therewith or incidental thereto and to settle all questions, difficulties or doubts that may arise in this regard at any stage without requiring the Board to secure any further consent or approval of the Members of the Company to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution."

**SPECIAL BUSINESS**

4. **To consider and approve an increase in remuneration of Mr. Ashish Narayan Sakalkar (DIN: 06601011), Managing Director of the Company;**

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Sections 178, 196, 197, and 198, read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 ("Act"), the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules made thereunder, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Articles of Association and the Nomination and Remuneration Policy of the Company, and pursuant to the recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors, consent of the Members be and is hereby accorded, by way of a Special Resolution, for revision and increase in the remuneration payable to Mr. Ashish Narayan Sakalkar (DIN: 06601011), Managing Director of the Company, to ₹6,50,000/- per month, inclusive of salary, allowances, benefits, perquisites and all other remuneration components with effect from 1 October 2026 up to 30 September 2029, subject to his valid reappointment or continuation as Managing Director of the Company in accordance with the applicable provisions of the Act as tenure of Mr. Ashish Narayan Sakalkar as Managing Director expires on 19 September 2029;

**RESOLVED FURTHER THAT** in addition to the aforesaid remuneration, Mr. Ashish Narayan Sakalkar shall be entitled to reimbursement of all reasonable and properly documented expenses actually incurred by him, wholly and exclusively in the performance of his official duties and in connection with the business of the Company, including expenses relating to travel, boarding, lodging, business hospitality, telephone, mobile and data connectivity, in accordance with the policies of the Company,

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



and such reimbursement shall not form part of his managerial remuneration to the extent permitted under applicable law.

**RESOLVED FURTHER THAT** notwithstanding anything contained herein, where, in any financial year during the aforesaid period, the Company has no profits or its profits are inadequate, the remuneration specified above shall be paid to Mr. Ashish Narayan Sakalkar as minimum remuneration, including where such remuneration exceeds the limits specified under Section 197 or Section II of Part II of Schedule V to the Act, subject to fulfilment of the conditions prescribed under Schedule V and receipt of such statutory, regulatory, lender or other approvals as may be required under applicable law.

**RESOLVED FURTHER THAT** the Board of Directors of the Company, including any committee thereof, and the Company Secretary or any other officer authorized by the Board, be and are hereby severally authorized to do all such acts, deeds, matters and things; execute or modify the employment agreement or memorandum of terms; make the necessary disclosures and filings with the Registrar of Companies, stock exchange(s) and other regulatory authorities; and settle any question, difficulty or doubt that may arise in connection with or incidental to giving effect to this Resolution."

**5. To consider and approve an increase in remuneration of Mrs. Saili Jayaram More Din 02691527, Whole Time Director and CEO of the Company,**

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Sections 178, 196, 197, and 198, read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 ("Act"), the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules made thereunder, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Articles of Association and the Nomination and Remuneration Policy of the Company, and pursuant to the recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors, consent of the Members be and is hereby accorded, by way of a Special Resolution, for revision and increase in the remuneration payable to Mrs. Saili Jayaram More (DIN: 02691527), Whole Time Director and CEO of the Company, to ₹6,50,000/- per month, inclusive of salary, allowances, benefits, perquisites and all other remuneration components with effect from 1 October 2026 up to 30 September 2029, subject to his valid reappointment or continuation as Whole Time Director and CEO of the Company in accordance with the applicable provisions of the Act as tenure of Mrs. Saili Jayaram More as Whole Time Director and CEO expires on 19 September 2029;

**RESOLVED FURTHER THAT** in addition to the aforesaid remuneration, Mrs. Saili Jayaram More shall be entitled to reimbursement of all reasonable and properly documented expenses actually incurred by him, wholly and exclusively in the performance of his official duties and in connection with the business of the Company, including expenses relating to travel, boarding, lodging, business hospitality,

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



telephone, mobile and data connectivity, in accordance with the policies of the Company, and such reimbursement shall not form part of his managerial remuneration to the extent permitted under applicable law.

**RESOLVED FURTHER THAT** notwithstanding anything contained herein, where, in any financial year during the aforesaid period, the Company has no profits or its profits are inadequate, the remuneration specified above shall be paid to Mrs. Saili Jayaram More as minimum remuneration, including where such remuneration exceeds the limits specified under Section 197 or Section II of Part II of Schedule V to the Act, subject to fulfilment of the conditions prescribed under Schedule V and receipt of such statutory, regulatory, lender or other approvals as may be required under applicable law.

**RESOLVED FURTHER THAT** the Board of Directors of the Company, including any committee thereof, and the Company Secretary or any other officer authorized by the Board, be and are hereby severally authorized to do all such acts, deeds, matters and things; execute or modify the employment agreement or memorandum of terms; make the necessary disclosures and filings with the Registrar of Companies, stock exchange(s) and other regulatory authorities; and settle any question, difficulty or doubt that may arise in connection with or incidental to giving effect to this Resolution."

**6. To consider and approve an increase in remuneration of Mr. Sachin Chandrakant Badakh, DIN 08685214, non-executive director of the Company,**

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Sections 178, 197, and 198, read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 ("Act"), the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules made thereunder, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Articles of Association and the Nomination and Remuneration Policy of the Company, and pursuant to the recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors, consent of the Members be and is hereby accorded, by way of a Special Resolution, for revision and increase in the remuneration payable to Mr. Sachin Chandrakant Badakh (DIN: 08685214), Non- Executive Director of the Company, to ₹2,50,000/- per month, inclusive of salary, allowances, benefits, perquisites and all other remuneration components with effect from 1 October 2026 up to 30 September 2029.

**RESOLVED FURTHER THAT** in addition to the aforesaid remuneration, Mr. Sachin Chandrakant Badakh shall be entitled to reimbursement of all reasonable and properly documented expenses actually incurred by him, wholly and exclusively in the performance of his official duties and in connection with the business of the Company, including expenses relating to travel, boarding, lodging, business hospitality, telephone, mobile and data connectivity, in accordance with the policies of the Company, and such reimbursement shall not form part of his managerial remuneration to the extent permitted under applicable law.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

**RESOLVED FURTHER THAT** notwithstanding anything contained herein, where, in any financial year during the aforesaid period, the Company has no profits or its profits are inadequate, the remuneration specified above shall be paid to Mr. Sachin Chandrakant Badakh as minimum remuneration, including where such remuneration exceeds the limits specified under Section 197 or Section II of Part II of Schedule V to the Act, subject to fulfilment of the conditions prescribed under Schedule V and receipt of such statutory, regulatory, lender or other approvals as may be required under applicable law.

**RESOLVED FURTHER THAT** the Board of Directors of the Company, including any committee thereof, and the Company Secretary or any other officer authorized by the Board, be and are hereby severally authorized to do all such acts, deeds, matters and things; execute or modify the employment agreement or memorandum of terms; make the necessary disclosures and filings with the Registrar of Companies, stock exchange(s) and other regulatory authorities; and settle any question, difficulty or doubt that may arise in connection with or incidental to giving effect to this Resolution."

For Asston Pharmaceuticals Limited

\_\_\_\_\_  
Rishi Upadhaya

Mem. No.: A74324

Company Secretary & Compliance Officer

**Date: 04-09-2026**

**Place: Mumbai**

**Notes:**

1. Statement pursuant to Section 102(1) of the Companies Act, 2013 ('Act'), in respect of the Businesses to be transacted at the 7<sup>th</sup> Annual General Meeting ('AGM') is annexed hereto.
2. The Ministry of Corporate Affairs ('MCA') has, vide its General Circular No. 03/2025 dated September 22, 2025 in relation to 'Clarification on holding of Annual General Meeting ('AGM') and Extraordinary General Meeting ('EGM') through Video Conferencing ('VC') or Other Audio Visual Means ('OAVM') read with Circular 20/2020 dated May 5, 2020, No. 14/2020 dated April 8, 2020, Circular No. 17/2020 dated April 13, 2020, Circular No. 33/2020 dated September 28, 2020, Circular No. 39/2020 dated December 31, 2020, Circular No. 10/2021 dated June 23, 2021, Circular No. 20/2021 dated December 8, 2021 and Circular No. 2/2022 dated May 5, 2022, Circular No. 10/2022 dated December 28, 2022, Circular No. 09/2023 dated September 25, 2023, Circular No. 09/2024 dated September 19, 2024 issued by the ('MCA') and Circular No. 03/2025 dated September 22, 2025 (hereinafter collectively referred to as 'MCA Circulars') allowed the companies to conduct their Annual General Meetings and Extraordinary General Meeting to be held **till further orders**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

through VC / OAVM, without the physical presence of the Members at a common venue by following the guidelines specified in the said MCA Circulars. Further, Securities and Exchange Board of India ('SEBI'), vide its circulars dated May 12, 2020, January 15, 2021, May 13, 2022, January 5, 2023 and October 3, 2024 ('SEBI Circulars') and other applicable circulars issued in this regard, have provided relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR').

3. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020, May 05, 2020, May 05, 2022 December 28, 2022, September, 25, 2023, September 19, 2024 and September, 22, 2025, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has arranged with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized e-voting agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by NSDL.
4. The Members can join the AGM in the VC/OAVM mode 15 minutes before the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on a first-come, first-served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors, etc. who are allowed to attend the AGM without restriction on account of a first-come, first-served basis.
5. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
6. Pursuant to the Circular No. 14/2020 dated 8th April, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint a proxy to attend and cast a vote for the Members is not available for this AGM. However, the Body Corporates are entitled to appoint authorized representatives to attend the AGM through VC/OAVM and participate thereat and cast their votes through e-voting.
7. In compliance with the MCA Circulars and SEBI Circulars, Notice of the AGM is being sent only through permitted mode to Members. Members may note that the Notice will also be available on the Company's website at <https://asstonpharmaceuticals.com/> and on the websites of the Stock Exchange, i.e., BSE Limited at [www.bseindia.com](http://www.bseindia.com). The AGM Notice is also available on the website of NSDL (agency for providing the Remote e- Voting facility), i.e., [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
8. In case of joint holders attending the AGM, only such joint holder who is higher in the order of names will be entitled to vote.
9. A person who is not a member as on the record date should treat this notice for information purposes only.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

10. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, PAN, registering of nomination and power of attorney, Bank Mandate details such as name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their DP in case the shares are held in electronic form and to the RTA in case the shares are held in physical form.
11. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any Member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned DP and holdings should be verified from time to time.
12. Members desiring inspection of statutory registers during the AGM may send their request in writing to the Company at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com).
13. Members who wish to inspect the relevant documents referred to in the Notice can send an e-mail to [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) up to the date of the AGM.
14. The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the Cut Off date, i.e. **Tuesday, 22<sup>nd</sup> September, 2026**.
15. M/s Pragma & Associates, Company Secretaries, Indore has been appointed by the Board of Directors of the Company as Scrutinizer for scrutinizing the voting process through E- Voting for the AGM fairly and transparently.
16. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting, by use of remote e-Voting system for all those Members who are present during the AGM through VC/OAVM but have not cast their votes by availing the remote e-Voting facility. The remote e-Voting shall be available by NSDL for voting 15 minutes after the conclusion of the Meeting.
17. The Scrutinizer shall, after the conclusion of voting at the AGM, first count the votes cast during the AGM and, thereafter, unblock the votes cast through remote e-Voting and shall make, not later than 2 working days from the conclusion of the AGM, a Consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
18. The Results declared, along with the Scrutinizer's Report, shall be placed on the Company's website <https://asstonpharmaceuticals.com/> immediately after the declaration of the result by the Chairman or a person authorized by him. The results shall also be immediately forwarded to the Stock Exchanges where the Company's Equity Shares are listed viz. BSE Limited at [www.bseindia.com](http://www.bseindia.com).
19. Members desirous of obtaining additional information regarding the subject matter of the Resolution can request at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com), so that the required information can be made available at the meeting, to the extent possible.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

20. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013 and all other documents referred to in the Notice will be available for inspection in electronic mode.
21. All documents referred to in the accompanying Notice are open to inspection by the members at the Registered Office of the Company on all working days up to the date of the 7<sup>th</sup> Annual General Meeting between 11:00 A.M. and 1:00 P.M.
22. The Members will be allowed to pose questions during the course of the Meeting. The queries can also be given in advance at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com).
23. In accordance with relevant Circulars issued by the Ministry of Corporate Affairs ("MCA"), the provisions of the Companies Act, 2013 ("Act") and the Listing Regulations, the 7<sup>th</sup> AGM of ASSTON PHARMACEUTICALS LIMITED ("the Company") is being held through VC without physical presence of Members at a common venue. The Registered Office of the Company shall be deemed to be the venue for the AGM

**THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER: -**

The remote e-voting period begins on **Saturday, 26<sup>th</sup> September, 2026, at 09:00 A.M. and ends on Monday, 28<sup>th</sup> September, 2026, at 05:00 P.M.** The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date), i.e., Tuesday 22<sup>nd</sup> September, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Tuesday 22<sup>nd</sup> September, 2026

**How do I vote electronically using NSDL e-Voting system?**

*The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:*

**Step 1: Access to NSDL e-Voting system**

**A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

**Login method for Individual shareholders holding securities in demat mode is given below:**

| Type of shareholders | Login Method |
|----------------------|--------------|
|----------------------|--------------|

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

|                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Individual Shareholders holding securities in demat mode with NSDL.</p> | <ol style="list-style-type: none"><li>1. For OTP based login you can click on <a href="https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp">https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp</a>. You will have to enter your 8-digit, DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li><li>2. Existing <b>IDeAS</b> user can visit the e-Services website of NSDL Viz. <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the “<b>Beneficial Owner</b>” icon under “<b>Login</b>” which is available under ‘<b>IDeAS</b>’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “<b>Access to e-Voting</b>” under e-Voting services and you will be able to see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li><li>3. If you are not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “<b>Register Online for IDeAS Portal</b>” or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li><li>4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li><li>5. Shareholders/Members can also download NSDL Mobile App “<b>NSDL Speede</b>” facility by scanning the QR code mentioned below for seamless voting experience.</li></ol> |
|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



|                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                    | <p style="text-align: center;"><b>NSDL Mobile App is available on</b></p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p> </div> <div style="text-align: center;">  <p>Google Play</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">   </div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Individual Shareholders holding securities in demat mode with CDSL | <ol style="list-style-type: none"> <li>1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login icon &amp; New System Myeasi Tab and then user your existing my easi username &amp; password.</li> <li>2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.</li> <li>3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login &amp; New System Myeasi Tab and then click on registration option.</li> <li>4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</li> </ol> |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

|                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Individual Shareholders (holding securities in demat mode) login through their depository participants | You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.**

| Login type                                                         | Helpdesk details                                                                                                                                                                                                           |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Individual Shareholders holding securities in demat mode with NSDL | Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at 022 - 4886 7000                                        |
| Individual Shareholders holding securities in demat mode with CDSL | Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800 22 55 33 |

**B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

**How to Log-in to NSDL e-Voting website?**

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

*Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.*

4. Your User ID details are given below:

| <b>Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical</b> | <b>Your User ID is:</b>                                                                                                                                        |
|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| a) For Members who hold shares in demat account with NSDL.            | 8 Character DP ID followed by 8 Digit Client ID<br><br>For example, if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.   |
| b) For Members who hold shares in demat account with CDSL.            | 16 Digit Beneficiary ID<br><br>For example, if your Beneficiary ID is 12***** then your user ID is 12*****                                                     |
| c) For Members holding shares in Physical Form.                       | EVEN Number followed by Folio Number registered with the company<br><br>For example, if folio number is 001*** and EVEN is 101456 then user ID is 101456001*** |

5. Password details for shareholders other than Individual shareholders are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
- If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
- If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered**.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



6. If you are unable to retrieve or have not received the “Initial password” or have forgotten your password:
  - a) Click on “**Forgot User Details/Password?**”(If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b) **Physical User Reset Password?**” (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - c) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
  - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

**Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.**

**How to cast your vote electronically and join General Meeting on NSDL e-Voting system?**

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote

**1. General guideline for shareholders:**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

2. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail [info@pragyaandassociates.com](mailto:info@pragyaandassociates.com) with a copy marked to [evoting@nsdl.com](mailto:evoting@nsdl.com). Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
3. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "[Forgot User Details/Password?](#)" or "[Physical User Reset Password?](#)" option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
4. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on.: 022 - 4886 7000 or send a request to Mr. Rahul Rajbhar at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)

**Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:**

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com).
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com). If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**
3. Alternatively, shareholder/members may send a request to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

**THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM/EGM ARE AS UNDER: -**

1. The procedure for e-Voting on the day of the AGM/EGM is same as the instructions mentioned above for remote e-voting.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

2. Only those Members/ shareholders, who will be present in the AGM/EGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM/EGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM/EGM. However, they will not be eligible to vote at the AGM/EGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM/EGM shall be the same person mentioned for Remote e-voting.

**INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:**

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under **"Join meeting"** menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) .The same will be replied by the company suitably.
6. Members who have questions or are seeking clarifications on the Notice or on the proposals as contained in this Notice are requested to send an e-mail to the Company at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) \_on or before Thursday, 24<sup>th</sup> September, 2026. This would enable the Company to compile the information and provide the replies at/after the meeting. The Company will allot time for members to express their views or give comments during the meeting. The members who wish to speak at the meeting need to register themselves as a speaker by sending an e-mail from their registered e-mail ID mentioning their name, DP ID and Client ID/Folio number and mobile number, on email ID [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) on or before Thursday, 24<sup>th</sup> September, 2026. Depending on the availability of time, the Company reserves the right to restrict the number of speakers at the meeting. Those shareholders who have registered themselves as speakers will only be allowed to express their views/ask questions during the meeting.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**EXPLANATORY STATEMENT PURSUANT TO THE PROVISIONS OF SECTION 102 OF THE COMPANIES ACT, 2013:**

**ITEM NO.: 03**

**To consider and approve the appointment of M/s Panchal S K & Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as statutory auditors of the Company.**

**Auditor Profile:**

M/s. Panchal S K & Associates (est. 2017, ICAI Reg. No. 145989W) is led by founder partner Swati Panchal, a member of ICAI since 2012. The firm comprises professionals focused on adding value to clients' businesses through technology-driven practices and insights. Its experience spans SMEs and larger corporates across various industries.

M/s. Panchal S K & Associates has a team of 25 professionals and has a 200+ client base including individuals, corporates, and QIBS. The firm has experience in **audit and assurance, statutory audit, internal and stock audit, compliance and forensic audit, revenue audit and tax audit**, with an emphasis on technology-driven audit practices and value addition to clients. Its professional experience extends across SMEs, corporates, banking institutions, NBFCs and other financial-sector entities.

The partners bring expertise in auditing, taxation, financial advisory, forensic accounting, corporate law, NBFC compliance and financial reporting. CA Swati Panchal holds certifications including DISA, Forensic Accounting, IBC, GST and Ind AS, while CA Krupal Panchal has qualifications/certifications including a PG Diploma in Forensic Accounting, DISA (ICAI) and QuickBooks ProAdvisor. The firm also has dedicated personnel for audit, finance, taxation and secretarial compliance functions, providing an institutional team-based approach to professional assignments.

Considering the firm's experience in statutory and assurance services, exposure to corporates, banking and NBFC clients, multidisciplinary professional team and technology-driven approach to audit and compliance, M/s. Panchal S K & Associates possesses relevant professional capabilities for undertaking the assignment of Statutory Auditors of the Company, subject to their eligibility, independence and compliance with the applicable provisions of the Companies Act, 2013, the rules made thereunder and other applicable regulatory requirements. The terms and conditions of the appointment and details as in accordance with regulation 36(5) of SEBI (Listing Regulations and Disclosure Requirements) Regulation 2015 are as follows;

| Sr. No | Particulars            | Details                                                                                                                                       |
|--------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | Proposed Fees Payable; | Rs. 5,00,000/- (Rs. Five Lakhs Only) excluding taxes and out-of-pocket expenses at actuals.                                                   |
| 2      | Term of appointment;   | M/s. Panchal S K & Associates shall be appointed for a term of 5 years from the conclusion of the 7 <sup>th</sup> Annual general meeting till |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

|   |                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                        | the conclusion of the 12 <sup>th</sup> Annual General Meeting.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 3 | Material changes in fees payable to the new auditor from that of the outgoing auditor; | No change in the fees payable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 4 | Basis of recommendation for appointment.                                               | <p>Audit Committee in its Meeting held on 4<sup>th</sup> September recommended the appointment to the Board of Directors based on the following points;</p> <ol style="list-style-type: none"><li>1. M/s. Panchal S K &amp; Associates has a team of 25 professionals and has a 200+ client base including individuals, corporates, and QIBS.</li><li>2. Wide range of services provided including but not limited to audit and assurance, statutory audit, internal and stock audit, compliance and forensic audit, revenue audit and tax audit.</li><li>3. The firm and the professional have experience in SMEs and listed entities.</li></ol> <p>Based on the above points Audit Committee recommended the appointment of M/s. Panchal S K &amp; Associates to the Board of Directors and the same was approved by the Board of Directors in the Board Meeting held on 04<sup>th</sup> September, 2026, subject to shareholder approval in the Annual General Meeting.</p> |

All the documents referred in the Notice are open for inspection at the Registered Office of the Company during 11:00 a.m. to 01:00 p.m., on all working days except Saturday, Sunday and Public Holidays up to the date of ensuing Annual General Meeting of the Company

The Board recommends the Ordinary Resolution set out in Item No.: 3 of the notice for approval of the Members.

**Item No.: 4 to 6.**

**Mr. Ashish Narayan Sakalkar** has been associated with the Company since its incorporation on 16th April, 2019, and has been entrusted with the overall management and affairs of the Company in his capacity as Managing Director, with effect from 20<sup>th</sup> September, 2024. He continues to serve as the Managing Director of the Company and has been appointed for a term of five years.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

Mr. Sakalkar possesses considerable experience in the fields of **Industrial Chemistry, Quality Assurance, and Regulatory Compliance**. In his capacity as Managing Director, he oversees the overall business operations of the Company and plays a key role in driving its strategic growth and development.

His responsibilities primarily include **business expansion, customer acquisition, development of business relationships, and negotiations with suppliers**. Through his professional expertise, industry knowledge, and strategic approach, he has made significant contributions to the Company's operations and has played an important role in strengthening its business and supporting its continued growth.

**Mrs. Saili Jayaram More** has been associated with the Company since its incorporation on 16 April 2019 and has been serving as the Whole-Time Director and CEO of the Company with effect from 20 September 2024. She has been entrusted with the overall management and affairs of the Company and has been appointed as Whole-Time Director and CEO for a term of five years. Accordingly, in accordance with the applicable provisions of the Companies Act, 2013, her five-year tenure shall expire on 19 September 2029.

Mrs. More possesses over 20 years of professional experience and has extensive expertise in supply chain management, procurement, and cost-effectiveness initiatives. Before joining the Company, she was associated with USV Limited as Deputy General Manager – Supply Chain (Procurement), where she gained valuable experience in procurement and cost optimization. She continues to leverage her professional expertise and experience in implementing cost-effective strategies and strengthening the Company's operational efficiency, thereby contributing to its sustainable growth and development.

**Mr. Sachin Chandrakant Badakh** has been associated with the Company since 2024 and currently serves as a Non-Executive Director of the Company. Mr. Badakh possesses over 10 years of experience in the pharmaceutical industry, with expertise in preparing regulatory dossiers tailored to client requirements and contributing to the development and implementation of comprehensive regulatory compliance strategies. Through his extensive knowledge, professional expertise, and industry experience, he has made valuable contributions to the Company's operations and has played an essential role in supporting the growth and development of the Company.

• **GENERAL INFORMATION**

| SNO. | PARTICULARS                                                                                                | DETAILS                  |
|------|------------------------------------------------------------------------------------------------------------|--------------------------|
| 1    | Nature of Industry                                                                                         | Pharmaceuticals Industry |
| 2    | Date or expected date of commencement of commercial production                                             | Not Applicable           |
| 3    | In case of new companies, expected date of commencement of activities as per project approved by financial | Not Applicable           |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

|   |                                                                                                              |                                              |              |
|---|--------------------------------------------------------------------------------------------------------------|----------------------------------------------|--------------|
|   | institutions appearing in the prospectus                                                                     |                                              |              |
| 4 | Financial performance based on given indicators (as per Audited Statements for the year ended on 31.03.2026) | Particulars                                  | Rs. In lakhs |
|   |                                                                                                              | Gross turnover including other income        | 3158.43      |
|   |                                                                                                              | Profit before interest, depreciation and tax | 555.01       |
|   |                                                                                                              | Interest                                     | 63.27        |
|   |                                                                                                              | Depreciation                                 | 32.40        |
|   |                                                                                                              | Profit before tax                            | 459.35       |
|   |                                                                                                              | Current tax                                  | 11.30        |
|   |                                                                                                              | Deferred tax                                 | 10.56        |
|   |                                                                                                              | Profit / (Loss) for the period               | 386.52       |
| 5 | Foreign investments or collaborations, if any                                                                | Not Applicable                               |              |

• **INFORMATION ABOUT THE APPOINTEE:**

| S. NO. | DETAILS                        | MR. ASHISH NARAYAN SAKALKAR                                                    | MR. SAILI JAYARAM MORE                                                               | MR. SACHIN CHANDRAKANT BADA KH                                                        |
|--------|--------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| 1      | Age                            | 50 years                                                                       | 56 years                                                                             | 39 years                                                                              |
| 2      | Director Identification Number | 06601011                                                                       | 02691527                                                                             | 08685214                                                                              |
| 3      | Date of first appointment      | 16th April, 2019                                                               | 16th April, 2019                                                                     | 17th May, 2024                                                                        |
| 4      | Background details.            | Mr. Ashish Narayan Sakalkar is the Promoter/ Managing Director of the Company. | Mrs. Saili Jayaram More is the Promoter/ Whole Time Director and CEO of the Company. | Mr. Sachin Chandrakant Badakh is the Promoter/ Non-Executive Director of the Company. |
| 5      | Qualification                  | Diploma in Regulatory Affairs, Master of Science (MSc) and PHD in              | Bachelor of Science (BSc) and Diploma in Material Management.                        | Bachelor of Pharmacy (BPharm) and                                                     |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

|    |                                               |                                                                                                                                                                                         |                                                                                                                                              |                                                                                                                                                                                                                  |
|----|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    |                                               | analytical chemistry.                                                                                                                                                                   |                                                                                                                                              | diploma in Pharmacy.                                                                                                                                                                                             |
| 6  | Experience                                    | He has vast experience of more than 20 years in the field of Industrial Chemistry, Quality Assurance and Regulation.                                                                    | She has overall Experience of above 20 years and previously worked with USV Limited as Deputy General Manager in Supply Chain (Procurement). | He possesses above 10 years of experience in Pharmaceutical industry and specialised in preparing dossiers suited perfectly to the client and contributing.                                                      |
| 7  | Past Remuneration.                            | Rs.3,25,000/- (Rupees Three Lakh Twenty-Five Thousand only) Per Month.                                                                                                                  | Rs.3,25,000/- (Rupees Three Lakh Twenty-Five Thousand only) Per Month.                                                                       | Rs. 1,25,000/- ( Rupees One Lakh Twenty-Five Thousand only) Per Month                                                                                                                                            |
| 8  | Terms and Condition                           | In accordance with the employment agreement.                                                                                                                                            | In accordance with the employment agreement.                                                                                                 | In accordance with the employment agreement.                                                                                                                                                                     |
| 9  | Recognition or awards.                        | Nil                                                                                                                                                                                     | Nil                                                                                                                                          | Nil                                                                                                                                                                                                              |
| 10 | No of Board Meetings attended during the year | 10 (attended all the Board Meetings held during the year)                                                                                                                               | 10 (attended all the Board Meetings held during the year)                                                                                    | 10 (attended all the Board Meetings held during the year)                                                                                                                                                        |
| 11 | Job profile and his suitability.              | He is working as Managing Director of the Company; he is in charge of business expansion, customer acquisition, development of business relationships, and negotiations with suppliers. | She is working as Whole Time Director and CEO of the Company; she is in charge of policy making, supply chain management, and procurement.   | He is working as Non-Executive Director of the Company; he is in charge of preparing regulatory dossiers tailored to client requirements and contributing to the development and implementation of comprehensive |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

|    |                                                                                                                     |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |
|----|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    |                                                                                                                     |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    | regulatory compliance strategies                                                                                                                                                                                                   |
| 12 | Remuneration proposed.                                                                                              | Rs. 6,50,000/- (Rupees Six Lakh Fifty Thousand only) Per Month.                                                                                                                                                                    | Rs. 6,50,000/- (Rupees Six Lakh Fifty Thousand only) Per Month.                                                                                                                                                                    | Rs. 2,50,000/- (Rupees Two Lakh Fifty Thousand only) Per Month.                                                                                                                                                                    |
| 13 | Comparative remuneration profile with respect to industry, size of the company, profile of the position and person. | Taking into account his capabilities and experience and the responsibilities shouldered by him, the aforesaid remuneration is commensurate with the remuneration package paid to similar appointees in other companies in general. | Taking into account her capabilities and experience and the responsibilities shouldered by him, the aforesaid remuneration is commensurate with the remuneration package paid to similar appointees in other companies in general. | Taking into account his capabilities and experience and the responsibilities shouldered by him, the aforesaid remuneration is commensurate with the remuneration package paid to similar appointees in other companies in general. |
| 14 | Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel, if any.  | Except for Managerial, no Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel.                                                                                               | Except for Managerial, no Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel.                                                                                               | Except for Managerial, no Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel.                                                                                               |
| 15 | Shareholding in the listed entity                                                                                   | 18,52,856                                                                                                                                                                                                                          | 18,52,856                                                                                                                                                                                                                          | 6,06,768                                                                                                                                                                                                                           |
| 16 | Relationship with other Directors inter se                                                                          | Not Related                                                                                                                                                                                                                        | Not Related                                                                                                                                                                                                                        | Not Related                                                                                                                                                                                                                        |
| 17 | Directorship in other listed                                                                                        | Nil                                                                                                                                                                                                                                | Nil                                                                                                                                                                                                                                | Nil                                                                                                                                                                                                                                |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

|    |                                                                                                                  |                                                                        |     |                                  |
|----|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----|----------------------------------|
|    | entities and listed entities from which the person has resigned in the past three years                          |                                                                        |     |                                  |
| 18 | Directorship in other limited and Private limited entities                                                       | Ferron Lifecare Private Limited and Arient Scientific Private Limited. | Nil | Ferron Lifecare Private Limited. |
| 19 | Membership / Chairmanship of Statutory Committees of other Boards as on in other listed entities March 31, 2026. | Nil                                                                    | Nil | Nil                              |

• **OTHER INFORMATION**

| SNO. | PARTICULARS                                         | DETAILS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1    | Reasons of loss or inadequate profits:              | The Company has earned adequate profits during the financial year under review. However, considering the dynamic business environment and uncertainties associated with market conditions and other factors beyond the Company's control, there may be instances during the tenure of the managerial personnel where the Company may have no profits or inadequate profits. Accordingly, the proposed remuneration is being proposed to be approved in accordance with the applicable provisions of Schedule V to the Companies Act, 2013, to enable the Company to remunerate the managerial personnel in such circumstances without any interruption. |
| 2    | Steps taken or proposed to be taken for improvement | The Company continues to undertake strategic initiatives to strengthen its sales and marketing efforts, expand its customer base, enhance operational efficiencies, and improve overall business performance. It also remains focused                                                                                                                                                                                                                                                                                                                                                                                                                   |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

|   |                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                         |
|---|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                   | on optimizing costs, strengthening customer relationships, and exploring new business opportunities, which are expected to contribute to sustained growth and improved profitability in the coming years.                                                                                                                                                                                               |
| 3 | Expected increase in productivity and profits in measurable terms | The Company is very conscious about improvement in productivity and is undertaking constant measures to improve it. In view of various steps taken by the Company, the Company is performing gradually better, and it is also expected to perform better in terms of profitability in the years to come. However, it might be difficult in the present scenario to predict profits in measurable terms. |

• **DISCLOSURES**

4. All elements of remuneration package such as salary, benefits, bonuses, stock options, pension, etc. of all the directors.
5. Details of fixed component and performance-linked incentives along with performance criteria- Remuneration of Directors is of fixed nature only.
6. Service contracts, notice period, severance fees- Nil
7. Stock options details, if any, and whether the same has been issued at a discount as well as the period over which accrued and over which exercisable- Nil

All the documents referred in the Notice are open for inspection at the Registered Office of the Company during 11:00 a.m. to 01:00 p.m., on all working days except Saturday, Sunday and Public Holidays up to the date of ensuing Annual General Meeting of the Company.

The Board recommends the special resolutions as set out in Item No. 4 to 6 of this Notice for your approval.

Except Mr. Ashish Narayan Sakalkar, Mrs. Saili Jayaram More and Me. Sachin Chandrakant Badakh, who are interested in this resolution, none of the Directors or Key Managerial Personnel (KMP) are interested in the resolutions.

**ANNEXURE TO THE NOTICE**

**DETAILS OF DIRECTORS SEEKING APPOINTMENT / RE-APPOINTMENT AT THE ANNUAL GENERAL MEETING**

Pursuant to Regulation 36(3) of SEBI (LODR) Regulations, 2015

|      |                             |
|------|-----------------------------|
| Name | Mr. Ashish Narayan Sakalkar |
| Age  | 50 years                    |
| DIN  | 06601011                    |

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

|                                                                                                                      |                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| First date of appointment                                                                                            | 16th April, 2019                                                                                                     |
| Date of Birth                                                                                                        | 30th May, 1976                                                                                                       |
| Qualifications                                                                                                       | Diploma in Regulatory Affairs, Master of Science (MSc) and PHD in analytical chemistry.                              |
| Experience                                                                                                           | He has vast experience in the field of Industrial Chemistry, Quality Assurance and Regulation.                       |
| Date of Appointment                                                                                                  | 16th April, 2019                                                                                                     |
| Proposed remuneration                                                                                                | Mentioned in item no 4 in the explanatory statement.                                                                 |
| Nature of his/her expertise in specific functional area                                                              | Business expansion, customer acquisition, and supplier negotiations.                                                 |
| Relationship between directors inter se                                                                              | Nil                                                                                                                  |
| Directorship in other listed entities and listed entities from which the person has resigned in the past three years | Nil                                                                                                                  |
| Membership / Chairmanship of Statutory Committees of other Boards as on March 31, 2026.                              | Nil                                                                                                                  |
| Past remuneration                                                                                                    | Mentioned in item no 4 in the explanatory statement.                                                                 |
| Terms and Conditions of Re-appointment                                                                               | As per the employment agreement.                                                                                     |
| Number of meetings of the Board attended                                                                             | 10 (Attended all the Board Meeting held during the year.)                                                            |
| Directorships of other Boards as on March 31, 2026                                                                   | Ferron Lifecare Private Limited and Arient Scientific Private Limited.                                               |
|                                                                                                                      |                                                                                                                      |
| Listed entities from which the Director has resigned in the past three years                                         | N.A.                                                                                                                 |
| Number of shares held in the company                                                                                 | 18,52,856 (Eighteen Lakh Fifty-Two Thousand Eight Hundred and Fifty-Six) equity shares of Rs. 10/- (Rupees Ten) each |
| Relationship with other Directors inter se                                                                           | Not Related.                                                                                                         |

**Brief Profile of Director:**

**Mr. Ashish Narayan Sakalkar**, aged 50 years, is the Managing Director of our Company. He has completed his Master of Science in the year 2001 from the Department of NMU, Jalgaon, and PHD from JNT University, and also a Diploma in Regulatory Affairs from the University of Delhi. He has good experience in the field of Industrial Chemistry, Quality Assurance, and Regulation. He handles the overall business operations of the company and mainly focuses on business expansion, customer acquisition, and negotiation with suppliers.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)